NewAmsterdam Pharma (NAMSW) Operating Leases (2022 - 2025)
Historic Operating Leases for NewAmsterdam Pharma (NAMSW) over the last 4 years, with Q3 2025 value amounting to $85000.0.
- NewAmsterdam Pharma's Operating Leases fell 6804.51% to $85000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $85000.0, marking a year-over-year decrease of 6804.51%. This contributed to the annual value of $202000.0 for FY2024, which is N/A changed from last year.
- Latest data reveals that NewAmsterdam Pharma reported Operating Leases of $85000.0 as of Q3 2025, which was down 6804.51% from $103000.0 recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Operating Leases registered a high of $328000.0 during Q2 2024, and its lowest value of $57133.8 during Q4 2022.
- In the last 4 years, NewAmsterdam Pharma's Operating Leases had a median value of $120000.0 in 2025 and averaged $155978.1.
- Its Operating Leases has fluctuated over the past 5 years, first soared by 37064.8% in 2024, then crashed by 6859.76% in 2025.
- NewAmsterdam Pharma's Operating Leases (Quarter) stood at $57133.8 in 2022, then increased by 21.98% to $69691.2 in 2023, then skyrocketed by 189.85% to $202000.0 in 2024, then plummeted by 57.92% to $85000.0 in 2025.
- Its Operating Leases stands at $85000.0 for Q3 2025, versus $103000.0 for Q2 2025 and $137000.0 for Q1 2025.